Access First News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Has pharma missed the boat? 28th April 2021 A year ago, amid deep concern over COVID-19 and frantic work to develop vaccines, some of pharma’s heaviest hitters saw the possibility of reputational enhancement. Novartis AG chief executive (CEO) Vas Narasimhan dubbed it a "remarkable, perhaps once-in-a generation opportunity" back in April during the company's first quarter earnings call. Eli Lilly CEO David Ricks, meanwhile, closely echoed this sentiment, stating the sector had a Indeed, the world watched news of vaccine development with bated breath. In the public mind, pharma companies cam...

717.5 -3.8% (1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents ...

(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or l...

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index Wednesday, January 27, 2021 11:40AM IST (6:10AM GMT)   Company Ranked Sixth Overall and Leads the Pharmaceutical Industry in Governance of Access Secured Industry-Leading Positions in All Three Technical Areas Evaluated Shows Strong Performance in Health System Strengthening and Compliance   (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas eval...

Press release content from Business Wire. The AP news staff was not involved in its creation. Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index January 26, 2021 GMT ( TSE:4502/NYSE:TAK ) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and ...